Indivior beats Dr Reddy's in the courts again
Indivior
769.00p
16:40 18/11/24
Indivior's lawyers have achieved another victory in the drug developer's ongoing US court battle, which will prevent rival Dr Reddy's Laboratories from selling its generic version of Suboxone Film.
FTSE 250
20,395.41
17:09 18/11/24
FTSE 350
4,473.50
17:09 18/11/24
FTSE All-Share
4,431.13
16:49 18/11/24
Pharmaceuticals & Biotechnology
19,204.40
17:09 18/11/24
The US Federal Court of Appeal has denied Dr Reddy's motion to block a preliminary injunction that was granted at the request of Indivior to prohibit the generic drugmaker from selling its buprenorphine/naloxone sublingual film product.
DRL appealed this ruling, and filed emergency motions seeking to speed up the appeal of the injunction and to delay the effect of the injunction pending a ruling on appeal.
The appeal court ruling means that Dr Reddy's continues to be prohibited from selling or offering to sell its generic product unless it wins its appeal, which has been set for early October.